Want to see ISPC full AI Analyst Report?
ISPC Stock Chart & Stats
$1.60
-$0.03(-1.03%)
At close: 4:00 PM EST
$1.60
-$0.03(-1.03%)
Day’s Range― - ―
52-Week Range$1.04 - $50.00
Previous CloseN/A
Volume25.67K
Average Volume (3M)1.07M
Market Cap
$2.87M
Enterprise Value$5.03
Total Cash (Recent Filing)$4.41M
Total Debt (Recent Filing)$240.90K
Price to Earnings (P/E)―
Beta1.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,518,590
10 Day Avg. Volume616,414
30 Day Avg. Volume1,068,751
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Marketplace Business ModelThe platform addresses a specialized research procurement problem by coordinating researchers and diverse specimen suppliers in one marketplace. Its role in sourcing, compliance, logistics, and data matching can support repeat usage and create operating leverage as transaction volume and supplier participation expand.
Digital Platform ExpansionContinued investment in marketplace functionality and integrations should improve accessibility, partner participation, and workflow efficiency. A broader digital infrastructure can strengthen the company’s ability to handle more complex specimen requests and scale service capabilities over the next several quarters.
AI Asset AcquisitionThe proposed Foldlab acquisition adds AI software, models, data rights, and related intellectual property that could broaden iSpecimen’s role beyond specimen access. If integration and approvals succeed, these assets may create additional research capabilities and support a more differentiated platform offering.
Bears Say
Revenue And Margin CollapseSharp revenue deterioration combined with negative gross profit indicates that the core service is currently operating at unfavorable economics. Persistent operating and net losses reduce reinvestment capacity and make it difficult to establish a durable path to profitability without substantial business improvement.
Persistent Cash BurnOngoing operating and free-cash-flow deficits show that the business is consuming cash rather than funding itself. This weakens financial flexibility, increases reliance on external capital, and could constrain investment in platform development or customer growth if funding becomes less available.
Nasdaq Compliance RiskThe Nasdaq deficiency creates a material business and financing risk because continued listing depends on demonstrating sufficient equity or another qualifying remedy. Failure to regain compliance could impair access to capital, reduce counterparties’ confidence, and complicate execution of the company’s strategy.
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
iSpecimen lowest stock price was $1.04 and its highest was $50.00 in the past 12 months.
What is iSpecimen’s market cap?
iSpecimen’s market cap is $2.87M.
When is iSpecimen’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iSpecimen’s earnings last quarter?
Currently, no data Available
Is iSpecimen overvalued?
According to Wall Street analysts iSpecimen’s price is currently Overvalued.
Does iSpecimen pay dividends?
iSpecimen does not currently pay dividends.
What is iSpecimen’s EPS estimate?
iSpecimen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iSpecimen have?
iSpecimen has 2,518,590 shares outstanding.
What happened to iSpecimen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of iSpecimen?
Currently, no hedge funds are holding shares in ISPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
iSpecimen
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Technical Analysis
―
Intelligent Bio Solutions
―
BioNexus Gene Lab Corp
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
2.52% Mutual Funds
― Other Institutional Investors
97.48% Public Companies and
Individual Investors